Bi Yonghua, Zhang Bo, Ren Jianzhuang, Han Xinwei, Wu Wenze
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Interventional Radiology, Jingzhou Central Hospital, The Second Clinical Medical College of Yangtze University, Jingzhou, China.
Front Pharmacol. 2022 Sep 29;13:992526. doi: 10.3389/fphar.2022.992526. eCollection 2022.
Drug-eluting beads transarterial chemoembolization (DEB-TACE) has not been widely used in patients with advanced and inoperable lung cancer. We aimed to report the preliminary outcomes of DEB-TACE with gemcitabine-loaded CalliSpheres beads for patients with advanced and inoperable lung cancer. From November 2017 to October 2021, 37 patients (29 males, mean age 64.7 ± 10.3 years) with advanced and inoperable lung cancer underwent DEB-TACE with gemcitabine-loaded CalliSpheres beads. The primary endpoint was overall response rate, and the secondary endpoints were overall survival and progression-free survival. A total of 54 sessions of DEB-TACE were performed in 37 patients, with a technique success rate of 100%. Fourteen patients received a second session of DEB-TACE. The mean follow-up time was 18.7 ± 11.9 months. After 1, 3, and 6 months, overall response rate and disease control rate were 27.8% and 91.7%, 25.8% and 74.2%, 32.1%, and 67.9%, respectively. The median progression-free survival was 8.8 months (95% CI 7.5, 12.5 months). The 3-, 6- and 12- month progression-free survival rates were 67.1%, 57.0%, and 30.1%, respectively. The median overall survival was 10.0 months (95% CI 4.5, 13.1 months). The 3-, 6-, and 12- month overall survival rates were 88.5%, 72.7%, and 40.9%, respectively. Minor complications were observed in 14 patients (37.8%), with no procedure-related deaths or severe adverse events. DEB-TACE with gemcitabine-loaded CalliSpheres beads is a safe, feasible and effective treatment strategy for patients with advanced and inoperable lung cancer.
载药微球经动脉化疗栓塞术（DEB-TACE）在晚期不可切除肺癌患者中尚未得到广泛应用。我们旨在报告使用载有吉西他滨的CalliSpheres微球进行DEB-TACE治疗晚期不可切除肺癌患者的初步结果。2017年11月至2021年10月，37例（29例男性，平均年龄64.7±10.3岁）晚期不可切除肺癌患者接受了载有吉西他滨的CalliSpheres微球DEB-TACE治疗。主要终点为总缓解率，次要终点为总生存期和无进展生存期。37例患者共进行了54次DEB-TACE治疗，技术成功率为100%。14例患者接受了第二次DEB-TACE治疗。平均随访时间为18.7±11.9个月。1、3和6个月后，总缓解率和疾病控制率分别为27.8%和91.7%、25.8%和74.2%、32.1%和67.9%。中位无进展生存期为8.8个月（95%CI 7.5，12.5个月）。3个月、6个月和12个月的无进展生存率分别为67.1%、57.0%和30.1%。中位总生存期为10.0个月（95%CI 4.5，13.1个月）。3个月、6个月和12个月的总生存率分别为88.5%、72.7%和40.9%。14例患者（37.8%）观察到轻微并发症，无手术相关死亡或严重不良事件。使用载有吉西他滨的CalliSpheres微球进行DEB-TACE是晚期不可切除肺癌患者一种安全、可行且有效的治疗策略。
